HER2-TARGETED THERAPIES
Long-Term Follow-Up Assessment of Cardiac Safety in SAFE-HEaRt, a Clinical Trial Evaluating the Use of HER2-Targeted Therapies in Patients With HER2-Positive Breast Cancer and Compromised Heart Function
Among 3-year follow-up data from the SAFE-HEaRt trial—presented during the Virtual 2020 ASCO Annual Meeting—involving 30 patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, or ado-trastuzumab emtansine, with asymptomatic left ventricular ejection fraction (LVEF) 40-49%, who were receiving beta blockers and/or ACE inhibitors/ARBs, mean LVEF was 51.5%, compared with 45% at baseline and 46% at end of treatment.
ASCO Annual Meeting 2020 (Abstract/Poster)
